Oncolytics Biotech (TSE:ONC) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Oncolytics Biotech is advancing toward FDA accelerated approval with promising trial results for their breast and pancreatic cancer treatments, particularly highlighting the success of their pelareorep + paclitaxel therapy in the BRACELET-1 trial. The company is also preparing for significant clinical milestones in 2025, including a study that could cement pelareorep as a key therapeutic option for breast cancer patients resistant to current treatments.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
